Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05732272 · ClinicalTrials.gov registry record · Phase 3
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
A Phase 3 study of Smoking Cessation, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT05732272: Recruiting Phase 3 study of Smoking Cessation, sponsored by University of Kansas Medical Center.
NCT05732272 is a Phase 3 study of Smoking Cessation that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 500 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05732272, a Phase 3 study of Smoking Cessation, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
Primary Outcome
Participants receiving extended bupropion treatment will have significantly higher Month 6 verified point-prevalence abstinence than participants receiving standard bupropion treatment.
Conditions Studied
Interventions
- DRUG Bupropion
Study Locations (1)
Missouri
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 3 |
What NCT05732272 shows while recruiting
NCT05732272 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which Bupropion is the first listed.
NCT05732272 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05732272 about?
NCT05732272 is a clinical study titled "Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment". This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
What is the current status of trial NCT05732272?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-02-28. Estimated completion is 2027-04-30.
What conditions does trial NCT05732272 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT05732272?
The interventions under investigation include: Bupropion (DRUG).
Who is sponsoring clinical trial NCT05732272?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05732272 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05732272's enrollment target sits among peer trials
500 53rd of 188 higher than 132 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
-
Nicotine Mouth Film for Craving Relief.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI